NCT03847506 (REVERT-K) is a Phase 4 clinical trial of Ezetimibe/Rosuvastatin in Hypertension, Hyperlipidemia, sponsored by HK inno.N Corporation.

Who is sponsoring NCT03847506?

NCT03847506 is sponsored by HK inno.N Corporation.

What drugs are being tested in NCT03847506?

Interventions in NCT03847506: Ezetimibe/Rosuvastatin, Candesartan cilexetil/Amlodipine besylate, Candesartan cilexetil.

What condition does NCT03847506 study?

NCT03847506 studies Hypertension, Hyperlipidemia.

Is NCT03847506 still recruiting?

NCT03847506 is currently completed. Last updated 10 May 2022.

Last reviewed 2022-05-10 · How we verify

NCT03847506: REVERT-K

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluate Efficacy and Safety of Ezetimibe/Rosuvastatin and Candesartan Cilexetil/Amlodipine Besylate Combination Tablets

Completed Phase 4 Last updated 10 May 2022

What this trial tests

Phase 4 trial testing Ezetimibe/Rosuvastatin in Hypertension, Hyperlipidemia in 127 participants. Completed in 2 December 2020.

Timeline

5 July 2018

Primary endpoint
2 December 2020

2 December 2020

Quick facts

Lead sponsor	HK inno.N Corporation
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	127
Start date	5 July 2018
Primary completion	2 December 2020
Estimated completion	2 December 2020
Sites	1 location across South Korea

Drugs / interventions tested

Ezetimibe/Rosuvastatin — full drug profile →
Candesartan cilexetil/Amlodipine besylate — full drug profile →
Candesartan cilexetil (CILEXETIL) — full drug profile →

Conditions studied

Hypertension, Hyperlipidemia — all drugs for Hypertension, Hyperlipidemia →

Sponsor

HK inno.N Corporation — full company profile →

Who can join

Adults 19 to 74, any sex, with Hypertension, Hyperlipidemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To evaluate the efficacy and the safety of concomitant use of Ezetimibe/Rosuvastatin combination tablets and Candesartan cilexetil/Amlodipine besylate combination tablets compared to each combination tablet alone in patients with essential hypertension (HTN) and hyperlipidemia.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Ezetimibe/Rosuvastatin

Trials testing the same drug.

NCT05889143 — A Study to Evaluate the Efficacy and Safety of CREZET Tablet · active not recruiting
NCT04158076 — Evaluating the Efficacy and Safety of Co-administrated Rosuvastatin/Ezetimibe and Telmisartan/Amlodipine · Phase 3 · completed
NCT03872232 — Evaluating the Efficacy and Safety of Co-administrated Rosuvastatin/Ezetimibe and Telmisartan · Phase 3 · completed
NCT03532854 — Evaluating a Pharmacokinetic Drug Interaction Between LGEV1801 and LGEV1802 · Phase 1 · completed

Other HK inno.N Corporation trials

Trials by the same sponsor.

NCT07277712 — A Study to Evaluate the Pharmacokinetics and Food-effect of IN-M00002 Tablet in Healthy Adult Volunteers · Phase 1 · not yet recruiting
NCT07192263 — Study to Evaluate the Efficacy and Safety of IN-B00009 Injection in Adults With Obesity or Overweight Without Diabetes M · Phase 3 · not yet recruiting
NCT06736912 — This Study Aims to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties and Food Effect of · Phase 1 · not yet recruiting
NCT06725355 — To Compare the Pharmacokinetics and Safety After a Single Dose Administration of IN-G00002 and IN-R00002 in Healthy Adul · Phase 1 · active not recruiting
NCT06332638 — PK, PD and Safety of Tegoprazan 12.5 mg After Oral Administration in Healthy Subjects · Phase 1 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03847506 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by HK inno.N Corporation
Last refreshed: 10 May 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03847506.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing